Dr. Ross I. Palis, MD

Dr. Palis practices at Colorado Allergy and Asthma Centers in Denver, Colorado.

Dr. Palis' NPI, 1669481701, was assigned on August 7, 2006. Dr. Palis graduated from Vanderbilt University School Of Medicine in 2002. Dr. Palis holds Colorado license 0065185.

Dr. Palis' primary practice is Colorado Allergy and Asthma Centers, at 125 N Rampart Way, Denver, CO 80230 in Denver County. The practice phone is (720) 858-7434.

Dr. Palis' primary practice is Colorado Allergy and Asthma Centers in Denver, Colorado. The medical group on file is Colorado Allergy & Asthma Centers. Dmand AI also links Dr. Palis to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Palis practices. Vendor and product names are available with a free account.

Allergy and immunology is Dr. Palis' primary specialty in the NPI Registry, under taxonomy code 207K00000X. Dr. Palis is board certified in allergy & immunology by the American Board of Allergy and Immunology. Dmand AI has Dr. Palis' licenses on file in 4 states: Colorado, Illinois, Missouri and Massachusetts.

Dmand AI lists acute sinusitis, asthma, chronic nasal allergies, hives, immune deficiency disease and upper respiratory infection (URI) among the conditions Dr. Palis treats.

CMS data shows 4,472 Medicare services from Dr. Palis across 11 procedure codes in 2024, for 196 Medicare patients. Medicare paid $52,648 for them. Every service was in an office.

CMS counts 196 Medicare patients who saw Dr. Palis in 2024. The largest group is 65 to 74, with 109 patients. 70% of them have high cholesterol, and 49% have arthritis. Their average risk score is 0.94, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Palis' median patient age at 44, with 59% women.

In 2024, Dr. Palis wrote 1,079 Medicare Part D claims for 204 patients. 48% of them were for generic drugs. CMS names the drug for 983 of them, across 25 drugs with 11 or more claims each, at $334,912 in total drug cost. In 2023, CMS named 825 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 65 out of 100 for Dr. Palis for performance year 2024, reported as part of a group. Dr. Palis accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 3 papers to Dr. Palis, published from 2008 to 2016. The most frequent topics are Desensitization, Immunologic, Drug Hypersensitivity and Antineoplastic Agents. Dr. Palis' most frequent co-authors are Henry Joseph Legere, MD, Tanya M. Laidlaw, MD and Supinda Bunyavanich, MD.

CMS Open Payments shows 337 general payments to Dr. Palis from 35 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 69% of the total. Teva Pharmaceuticals USA, Inc. paid the most, $3,496.

Dmand AI lists 1 award for Dr. Palis, most recently CMS Stage 1 EHR in 2013.

Dr. Palis graduated from Vanderbilt University School Of Medicine in 2002. Dr. Palis is a member of AAAAI and ACAAI.

Dr. Palis is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.